GT201100322A - Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a - Google Patents

Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a

Info

Publication number
GT201100322A
GT201100322A GT201100322A GT201100322A GT201100322A GT 201100322 A GT201100322 A GT 201100322A GT 201100322 A GT201100322 A GT 201100322A GT 201100322 A GT201100322 A GT 201100322A GT 201100322 A GT201100322 A GT 201100322A
Authority
GT
Guatemala
Prior art keywords
phenylimidazol
inhibitors
new derivatives
pde10a
enzyme
Prior art date
Application number
GT201100322A
Other languages
English (en)
Inventor
Ritzén Andreas
Kehler Jan
Langgård Morten
Nielsen Jacob
Kilburn John Paul
Mohamed M Farah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2009/050134 external-priority patent/WO2009152825A1/en
Application filed filed Critical
Publication of GT201100322A publication Critical patent/GT201100322A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO QUE ES UN INHIBIDOR DE LA ENZIMA PDE10A Y, COMO TAL, SIRVE PARA TRATAR TRASTORNOS NEURODEGENERATIVOS Y PSIQUIÁTRICOS. LA INVENCIÓN TAMBIÉN SE REFIERE A LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN EL COMPUESTO DE ESTA INVENCIÓN Y MÉTODOS PARA TRATAR TRASTORNOS USANDO EL COMPUESTO DE LA INVENCIÓN.
GT201100322A 2009-06-19 2011-12-14 Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a GT201100322A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/050134 WO2009152825A1 (en) 2008-06-20 2009-06-19 Novel phenylimidazole derivatives as pde10a enzyme inhibitors

Publications (1)

Publication Number Publication Date
GT201100322A true GT201100322A (es) 2014-02-06

Family

ID=42321053

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201100322A GT201100322A (es) 2009-06-19 2011-12-14 Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a

Country Status (27)

Country Link
EP (1) EP2443105B1 (es)
JP (1) JP5768044B2 (es)
AR (1) AR077144A1 (es)
AU (1) AU2010262190B2 (es)
CA (1) CA2765750A1 (es)
CR (1) CR20110654A (es)
CY (1) CY1115971T1 (es)
DK (1) DK2443105T3 (es)
DO (1) DOP2011000397A (es)
ES (1) ES2527216T3 (es)
GE (1) GEP20146100B (es)
GT (1) GT201100322A (es)
HR (1) HRP20141222T1 (es)
IL (1) IL216684A (es)
MA (1) MA33367B1 (es)
MX (1) MX2011013400A (es)
MY (1) MY156785A (es)
NZ (1) NZ597203A (es)
PL (1) PL2443105T3 (es)
PT (1) PT2443105E (es)
SG (1) SG176680A1 (es)
SI (1) SI2443105T1 (es)
SM (1) SMT201500003B (es)
TW (1) TW201100430A (es)
UA (2) UA102693C2 (es)
WO (1) WO2010145668A1 (es)
ZA (1) ZA201109271B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
CN103874701A (zh) * 2011-09-09 2014-06-18 H.隆德贝克有限公司 吡啶化合物和其用途
WO2013034755A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
WO2013034758A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
WO2020094592A1 (en) * 2018-11-06 2020-05-14 H. Lundbeck A/S Compounds for treating negative symptoms and cognitive impairments
BR112020013743A2 (pt) * 2018-11-06 2020-12-01 H. Lundbeck A/S hemiadipato de 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
AU2003262023A1 (en) 2002-09-10 2004-04-30 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
JP2006509832A (ja) 2002-10-30 2006-03-23 ニューロ３デー サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用
MXPA05013822A (es) 2003-06-30 2006-02-28 Altana Pharma Ag Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
CA2530114A1 (en) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
CA2556413A1 (en) * 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20060160814A1 (en) 2004-09-03 2006-07-20 Arrington Mark P Phosphodiesterase 10 inhibitors
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP1991530A1 (en) * 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
CA2765750A1 (en) 2010-12-23
CR20110654A (es) 2012-03-09
MA33367B1 (fr) 2012-06-01
EP2443105A1 (en) 2012-04-25
GEP20146100B (en) 2014-05-27
AU2010262190A1 (en) 2012-01-19
DK2443105T3 (en) 2015-01-12
IL216684A0 (en) 2012-02-29
ES2527216T3 (es) 2015-01-21
SMT201500003B (it) 2015-03-05
DOP2011000397A (es) 2012-07-15
ZA201109271B (en) 2013-02-27
JP2012530086A (ja) 2012-11-29
TW201100430A (en) 2011-01-01
IL216684A (en) 2016-03-31
AR077144A1 (es) 2011-08-03
HRP20141222T1 (hr) 2015-02-27
PT2443105E (pt) 2015-01-14
EP2443105B1 (en) 2014-10-29
UA102693C2 (ru) 2013-08-12
AU2010262190B2 (en) 2013-01-31
CY1115971T1 (el) 2017-01-25
MX2011013400A (es) 2012-02-21
SG176680A1 (en) 2012-01-30
NZ597203A (en) 2013-03-28
JP5768044B2 (ja) 2015-08-26
SI2443105T1 (sl) 2015-02-27
WO2010145668A1 (en) 2010-12-23
PL2443105T3 (pl) 2015-03-31
MY156785A (en) 2016-03-31
UA106378C2 (ru) 2014-08-26

Similar Documents

Publication Publication Date Title
GT201100322A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
GT201300124A (es) Inhibidores de nampt y rock
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
CO6771447A2 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
GT201000143A (es) Inhibidores de beta-lactamasa
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CR20130233A (es) Derivados que quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinaza
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
GT201400090A (es) 2-tiopirimidinonas
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
HN2009001165A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
GT201200180A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CR20130024A (es) Compuestos heterocíclicos fusionados
GT201300130A (es) Derivados de imidazol como inhibidores de la enzima pde10a
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA